Skip to content
phase 2Weight Loss & Diabetes

Amylin

Also known as: Islet Amyloid Polypeptide, IAPP, Diabetes-Associated Peptide, DAP, Insulinoma Amyloid Peptide

Amylin (islet amyloid polypeptide/IAPP) is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in a ~1:100 molar ratio. It was discovered in 1987 as the primary component of amyloid deposits found in the pancreatic islets of type 2 diabetes patients. Amylin complements insulin's actions by slowing gastric emptying, suppressing postprandial glucagon secretion, and promoting satiety. Its synthetic analog pramlintide (Symlin) is FDA-approved, and next-generation long-acting amylin analogs (cagrilintide in CagriSema) represent one of the most promising frontiers in obesity pharmacotherapy.

3 cited references·5 researched benefits

Quick Answer

Amylin (IAPP) is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells. It regulates postprandial glucose by slowing gastric emptying, suppressing glucagon, and promoting satiety. Amylin is deficient in type 1 diabetes (beta cells destroyed) and impaired in type 2 diabetes. Its analog pramlintide (Symlin) is FDA-approved for diabetes, and next-generation amylin analogs like cagrilintide are in phase 3 trials for obesity as part of dual-agonist combinations.

Key Facts

Mechanism
Amylin acts primarily through calcitonin receptor/receptor activity-modifying protein (RAMP) complexes, particularly AMY1 (CTR + RAMP1), AMY2 (CTR + RAMP2), and AMY3 (CTR + RAMP3) receptors. These are expressed in the area postrema, nucleus tractus solitarius, and hypothalamus. Activation produces three complementary effects: (1) slowing of gastric emptying by 50–70%, reducing the rate of glucose appearance in blood; (2) suppression of postprandial glucagon secretion from pancreatic alpha cells, preventing inappropriate hepatic glucose output; and (3) activation of satiety circuits that reduce meal size by ~20–25%. Amylin also has minor effects on bone metabolism and may modulate lipolysis. Native amylin is prone to aggregation into amyloid fibrils — a pathological process that contributes to beta cell death in type 2 diabetes.
Research Status
phase 2
Half-Life
~15 minutes
Molecular Formula
C₁₆₅H₂₆₁N₅₁O₅₅S₂
Primary Use
Weight Loss & Diabetes
Table of Contents

Benefits

  • Slows gastric emptying by 50–70%, reducing postprandial glucose spikes when co-administered with insulinstrong
  • Suppresses inappropriate postprandial glucagon secretion, complementing insulin's glucose-lowering actionstrong
  • Promotes satiety and reduces food intake by 20–25% per meal through CNS appetite regulationstrong
  • Weight loss promotion — amylin analogs produce 1–4 kg weight loss without the weight gain typical of insulin therapymoderate
  • Next-generation long-acting amylin analogs (cagrilintide) show >20% body weight loss when combined with semaglutide in phase 3 trialsmoderate

Dosage Protocols

RouteDosage RangeFrequencyNotes
Subcutaneous injection (as pramlintide analog)60–120 mcgBefore major meals (2–3× daily)Native amylin is not used therapeutically due to aggregation issues. Pramlintide (3 proline substitutions) is the approved analog. Reduce mealtime insulin by 50% at initiation.
Research (native amylin)10–50 mcgSingle dose or short-term infusionNative amylin is used in research settings to study physiology and amyloidogenesis. Not suitable for chronic administration due to fibril formation risk.

Medical disclaimer

Dosage information is provided for educational reference only. Always follow your prescriber's instructions and consult a qualified healthcare provider before starting any peptide protocol.

Side Effects

  • Nausea — the most common side effect of amylin analogs, affecting 30–50% of patients initiallycommon
  • Hypoglycemia — risk increases when combined with insulin; dose reduction of mealtime insulin requiredserious
  • Amyloid fibril formation — native amylin aggregates into toxic amyloid deposits that kill beta cells in type 2 diabetesserious
  • Reduced appetite — sometimes classified as therapeutic but can lead to excessive caloric restrictioncommon
  • Vomiting at higher doses or without proper dose titrationcommon

Frequently Asked Questions

What is the relationship between amylin and type 2 diabetes?
Amylin has a dual role in type 2 diabetes. Normally, it helps regulate glucose by slowing digestion and suppressing glucagon. However, human amylin has an intrinsic tendency to misfold and aggregate into amyloid fibrils — toxic protein deposits that accumulate in the pancreatic islets. These amyloid deposits are found in 90%+ of type 2 diabetes patients at autopsy and are believed to contribute to progressive beta cell death. This creates a vicious cycle: as beta cells die, both insulin and amylin production decrease, worsening both glucose control and the loss of amylin's beneficial effects.
Why can't native amylin be used as a drug?
Human amylin aggregates into amyloid fibrils under pharmaceutical storage and physiological conditions, making it unsuitable for injection. The proline-rich region at positions 20–29 is the amyloidogenic "hot spot." Pramlintide (the FDA-approved analog) has three proline substitutions at positions 25, 28, and 29 that prevent fibril formation while retaining full receptor activity. Interestingly, rat amylin naturally has prolines at these positions and does not form amyloid — rats do not develop islet amyloid or amylin-related beta cell death.
What is CagriSema and how does it relate to amylin?
CagriSema is Novo Nordisk's combination of cagrilintide (a next-generation long-acting amylin analog) with semaglutide (a GLP-1 receptor agonist). Cagrilintide is engineered for once-weekly dosing (versus pramlintide's 2–3× daily), with an acylated fatty acid chain that extends its half-life through albumin binding. In phase 3 trials, the combination produces approximately 20–25% body weight loss, suggesting that amylin and GLP-1 pathways are synergistic for appetite suppression and weight management. CagriSema represents the evolution of amylin-based therapy from pramlintide's diabetes focus to obesity treatment.
How does amylin differ from GLP-1 in appetite regulation?
Both amylin and GLP-1 reduce appetite, but through distinct pathways. Amylin acts primarily through calcitonin receptors (CTR/RAMP complexes) in the area postrema and brainstem, promoting meal-by-meal satiety and slowing gastric emptying. GLP-1 acts through GLP-1 receptors in the hypothalamus, brainstem, and gut, reducing both hunger and food reward signaling. Because they use different receptors and neural circuits, their effects are additive or synergistic when combined — which is why CagriSema (amylin + GLP-1) produces greater weight loss than either mechanism alone.

References

  1. 1
    Islet amyloid polypeptide: biology, pathophysiology, and therapeutic opportunities in type 2 diabetes(2008)PubMed ↗
  2. 2
    Amylin: pharmacology, physiology, and clinical potential for the treatment of obesity and diabetes(2015)PubMed ↗
  3. 3
    Amylin and its analogs: physiology, pharmacology, and therapeutic potential in diabetes and obesity(2011)PubMed ↗

Latest Research

Last updated: 2026-02-19